KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell LymphomaMichael Wang, Patrick M. Reagan, Nöel Milpied et al.|New England Journal of Medicine|2020Cited by 1.9k
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Journal of Clinical Oncology|2022Cited by 331
KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL): Results of the Phase 2 ZUMA-2 StudyMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Blood|2019Cited by 23
One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell LymphomaMichael Wang, Patrick M. Reagan, Javier Muñoz et al.|Blood|2020Cited by 14
Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).Michael Wang, Patrick M. Reagan, Javier Muñoz et al.|Journal of Clinical Oncology|2021Cited by 10